Apoptosis genes and resistance to cancer therapy: What do the experimental and clinical data tell us?

Cancer Biology and Therapy

Volumn 2, Issue 5, 2003, Pages 477-490

  Brown, Martin ^a   Wilson, George ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Bcl 2; Cancer therapy; DNA repair; p53; Radiotherapy; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; APOPTOSIS; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 1542472979     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.5.450     Document Type: Review

References (213)

1. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997; 89:1845-53. (Pubitemid 27132097)
2. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98:2603-14.
3. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999; 187:127-37. (Pubitemid 29009842)
4. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108:153-64. (Pubitemid 34161136)
5. Debatin KM, Poncet D, Kroemer G. Chemotherapy: Targeting the mitochondrial cell death pathway. Oncogene 2002; 21:8786-803. (Pubitemid 36132400)
6. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109:335-46. (Pubitemid 34606876)
7. Schmitt CA. Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer 2003; 3:286-95. (Pubitemid 37328864)
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70. (Pubitemid 30046295)
9. Ruth AC, Roninson IB. Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. Cancer Res 2000; 60:2576-8. (Pubitemid 30318226)
10. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003; 3:117-29. (Pubitemid 37328879)
11. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997; 278:1064-8. (Pubitemid 27517876)
12. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000; 407:810-6.
13. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003; 3:17-22. (Pubitemid 37443888)
14. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7:542-7. (Pubitemid 33127139)
15. Vaux DL. Apoptosis and toxicology - what relevance? Toxicology 2002; 181-182:3-7.
16. Stadelmann C, Lassmann H. Detection of apoptosis in tissue sections. Cell Tissue Res 2000; 301:19-31. (Pubitemid 30459852)
17. Frankfurt OS, Robb JA, Sugarbaker EV, Villa L. Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: Relation to bcl-2 expression, hormone receptors, and lymph node metastases. Clin Cancer Res 1997; 3:465-71. (Pubitemid 27158072)
18. Jain D, Srinivasan R, Patel FD, Kumari Gupta S. Evaluation of p53 and Bcl-2 expression as prognostic markers in invasive cervical carcinoma stage IIb/III patients treated by radiotherapy. Gynecol Oncol 2003; 88:22-8. (Pubitemid 36062661)
19. Gasinska A, Urbanski K, Gruchala A, Biesaga B, Kojs Z. A ratio of apoptosis to mitosis, proliferation pattern and prediction of radiotherapy response in cervical carcinoma. Neoplasma 2002; 49:379-86. (Pubitemid 36139238)
20. Kim JY, Cho HY, Lee KC, Hwang YJ, Lee MH, Roberts SA, et al. Tumor apoptosis in cervical cancer: Its role as a prognostic factor in 42 radiotherapy patients. Int J Cancer 2001; 96:305-12. (Pubitemid 32946476)
21. Liu SS, Tsang BK, Cheung AN, Xue WC, Cheng DK, Ng TY, et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer 2001; 37:1104-10.
22. Zaghloul MS, El Naggar M, El Deeb A, Khaled H, Mokhtar N. Prognostic implication of apoptosis and angiogenesis in cervical uteri cancer. Int J Radiat Oncol Biol Phys 2000; 48:1409-15.
23. Paxton JR, Bolger BS, Armour A, Symonds RP, Mao JH, Burnett RA. Apoptosis in cervical squamous carcinoma: Predictive value for survival following radiotherapy. J Clin Pathol 2000; 53:197-200. (Pubitemid 30163602)
24. Chung EJ, Seong J, Yang WI, Park TK, Kim JW, Suh CO, et al. Spontaneous apoptosis as a predictor of radiotherapy in patients with stage IIB squamous cell carcinoma of the uterine cervix. Acta Oncol 1999; 38:449-54. (Pubitemid 29305719)
25. Sheridan MT, Cooper RA, West CM. A high ratio of apoptosis to proliferation correlates with improved survival after radiotherapy for cervical adenocarcinoma. Int J Radiat Oncol Biol Phys 1999; 44:507-12. (Pubitemid 29258423)
26. Tsang RW, Wong CS, Fyles AW, Levin W, Manchul LA, Milosevic M, et al. Tumour proliferation and apoptosis in human uterine cervix carcinoma II: Correlations with clinical outcome. Radiother Oncol 1999; 50:93-101. (Pubitemid 29136743)
27. Levine EL, Davidson SE, Roberts SA, Chadwick CA, Potten CS, West CM. Apoptosis as predictor of response to radiotherapy in cervical carcinoma. Lancet 1994; 344:472. (Pubitemid 24248260)
28. Wheeler JA, Stephens LC, Tornos C, Eifel PJ, Ang KK, Milas L, et al. ASTRO Research Fellowship: Apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 1995; 32:1487-93.
29. Yuki H, Fujimura M, Yamakawa Y, Hidaka T, Saito S. Detection of apoptosis and expression of apoptosis-associated proteins as early predictors of prognosis after irradiation therapy in stage IIIb uterine cervical cancer. Jpn J Cancer Res 2000; 91:127-34. (Pubitemid 30128947)
30. Lyng H, Sundfor K, Rofstad EK. Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: Relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis. Int J Radiat Oncol Biol Phys 2000; 46:935-46. (Pubitemid 30114407)
31. Niibe Y, Nakano T, Ohno T, Tsujii H, Oka K. Relationship between p21/WAF-1/CIP-1 and apoptosis in cervical cancer during radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44:297-303. (Pubitemid 29205025)
32. Kokawa K, Shikone T, Otani T, Nakano R. Transient increases of apoptosis and Bax expression occurring during radiotherapy in patients with invasive cervical carcinoma. Cancer 1999; 86:79-87. (Pubitemid 29293380)
33. Ohno T, Nakano T, Niibe Y, Tsujii H, Oka K. Bax protein expression correlates with radiation- induced apoptosis in radiation therapy for cervical carcinoma. Cancer 1998; 83:103-10. (Pubitemid 28299635)
34. Grabenbauer GG, Suckorada O, Niedobitek G, Rodel F, Iro H, Sauer R, et al. Imbalance between proliferation and apoptosis may be responsible for treatment failure after postoperative radiotherapy in squamous cell carcinoma of the oropharynx. Oral Oncol 2003; 39:459-69. (Pubitemid 36579113)
35. Tsuchiya K, Shirato H, Nishioka T, Yamazaki A, Hashimoto S, Kagei K, et al. Pretreatment apoptotic scores do not predict response to radiation therapy in oropharyngeal squamous cell carcinoma. Oral Oncol 2001; 37:159-63. (Pubitemid 32146662)
36. Mandal AK, Verma D, Mohanta PK, Saha R, Maeda T, Sugino T, et al. Prognostic significance of apoptosis in squamous cell carcinoma of oral cavity with special reference to TNM stage, histological grade and survival. Indian J Pathol Microbiol 2001; 44:257-9.
37. Stoll C, Baretton G, Ahrens C, Lohrs U. Prognostic significance of apoptosis and associated factors in oral squamous cell carcinoma. Virchows Arch 2000; 436:102-8. (Pubitemid 30128755)
38. Sikorska B, Wagrowska-Danilewicz M, Danilewicz M. Prognostic significance of apoptosis in laryngeal cancer. A quantitative immunomorphological study. Acta Histochem 2000; 102:413-25.
39. Xie X, De Angelis P, Clausen OP, Boysen M. Prognostic significance of proliferative and apoptotic markers in oral tongue squamous cell carcinomas. Oral Oncol 1999; 35:502-9. (Pubitemid 29386787)
40. Pulkkinen JO, Klemi P, Martikainen P, Grenman R. Apoptosis in situ, p53, bcl-2 and AgNOR counts as prognostic factors in laryngeal carcinoma. Anticancer Res 1999; 19:703-7.
41. Hirvikoski P, Kumpulainen E, Virtaniemi J, Pirinen R, Salmi L, Halonen P, et al. Enhanced apoptosis correlates with poor survival in patients with laryngeal cancer but not with cell proliferation, bcl-2 or p53 expression. Eur J Cancer 1999; 35:231-7. (Pubitemid 29136773)
42. Lera J, Lara PC, Perez S, Cabrera JL, Santana C. Tumor proliferation, p53 expression, and apoptosis in laryngeal carcinoma: Relation to the results of radiotherapy. Cancer 1998; 83:2493-501. (Pubitemid 29019568)
43. Giannopoulou I, Nakopoulou L, Zervas A, Lazaris AC, Stravodimos C, Giannopoulos A, et al. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: Prognostic implications. Urol Res 2002; 30:342-5.
44. Moonen L, Ong F, Gallee M, Verheij M, Horenblas S, Hart AA, et al. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 2001; 49:1305-10. (Pubitemid 32294311)
45. Lavezzi AM, Biondo B, Cazzullo A, Giordano F, Pallotti F, Turconi P, et al. The role of different biomarkers (DNA, PCNA, apoptosis and karyotype) in prognostic evaluation of superficial transitional cell bladder carcinoma. Anticancer Res 2001; 21:1279-84. (Pubitemid 32494133)
46. Rodel C, Grabenbauer GG, Rodel F, Birkenhake S, Kuhn R, Martus P, et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: Possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000; 46:1213-21.
47. Korkolopoulou P, Konstantinidou AE, Christodoulou P, Patsouris E, Thomas-Tsangli E, Kapralos P, et al. Apoptosis in bladder carcinomas detected with monoclonal antibody to single-stranded DNA: Relation to cell cycle regulators and survival. Urology 2000; 56:516-20. (Pubitemid 30658200)
48. Harada S, Sato R, Nakamura R, Oikawa H, Ohgi S, Tamakawa Y, et al. The correlation between spontaneous and radiation-induced apoptosis in T3B bladder cancer (histological grade G3), and the precedence between the two kinds of apoptosis for predicting clinical prognosis. Int J Radiat Oncol Biol Phys 2000; 48:1059-67.
49. Lara PC, Perez S, Rey A, Santana C. Apoptosis in carcinoma of the bladder: Relation with radiation treatment results. Int J Radiat Oncol Biol Phys 1999; 43:1015-9. (Pubitemid 29144788)
50. Chyle V, Pollack A, Czerniak B, Stephens LC, Zagars GK, Terry NH, et al. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 1996; 35:281-7.
51. Noguchi T, Kikuchi R, Ono K, Takeno S, Moriyama H, Uchida Y. Prognostic significance of p27/kip1 and apoptosis in patients with colorectal carcinoma. Oncol Rep 2003; 10:827-31.
52. Marijnen CA, Nagtegaal ID, Mulder-Stapel AA, Schrier PI, van de Velde CJ, van Krieken JH, et al. High intrinsic apoptosis, but not radiation-induced apoptosis, predicts better survival in rectal carcinoma patients. Int J Radiat Oncol Biol Phys 2003; 57:434-43. (Pubitemid 37040940)
53. Bendardaf R, Ristamaki R, Kujari H, Laine J, Lamlum H, Collan Y, et al. Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma. Oncology 2003; 64:435-42. (Pubitemid 36682959)
54. Rodel C, Grabenbauer GG, Papadopoulos T, Bigalke M, Gunther K, Schick C, et al. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 2002; 52:294-303. (Pubitemid 34172996)
55. Michael-Robinson JM, Reid LE, Purdie DM, Biemer-Huttmann AE, Walsh MD, Pandeya N, et al. Proliferation, apoptosis, and survival in high-level microsatellite instability sporadic colorectal cancer. Clin Cancer Res 2001; 7:2347-56. (Pubitemid 32751635)
56. Adell GC, Zhang H, Evertsson S, Sun XF, Stal OH, Nordenskjold BA. Apoptosis in rectal carcinoma: Prognosis and recurrence after preoperative radiotherapy. Cancer 2001; 91:1870-5. (Pubitemid 32424113)
57. Schwandner O, Schiedeck TH, Bruch HP, Duchrow M, Windhoevel U, Broll R. Apoptosis in rectal cancer: Prognostic significance in comparison with clinical histopathologic, and immunohistochemical variables. Dis Colon Rectum 2000; 43:1227-36.
58. Sinicrope FA, Hart J, Hsu HA, Lemoine M, Michelassi F, Stephens LC. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin Cancer Res 1999; 5:1793-804. (Pubitemid 29334461)
59. Vaquero J, Zurita M, Coca S, Oya S. Imbalance between apostain expression and proliferative index can predict survival in primary glioblastoma. Acta Neurochir (Wien) 2002; 144:151-5; discussion 155-6.
60. Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ungersbock K, et al. Prognostic relevance of p53 protein expression in glioblastoma. Oncol Rep 2002; 9:703-7.
61. Heesters MA, Koudstaal J, Go KG, Molenaar WM. Analysis of proliferation and apoptosis in brain gliomas: Prognostic and clinical value. J Neurooncol 1999; 44:255-66. (Pubitemid 30113525)
62. Kuriyama H, Lamborn KR, O'Fallon JR, Iturria N, Sebo T, Schaefer PL, et al. Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas. Neuro-oncol 2002; 4:179-86. (Pubitemid 35214754)
63. Matturri L, Colombo B, Lavezzi AM. Evidence for apoptosis in nonsmall cell lung carcinoma. Relationship with cell kinetics and prognosis. Anal Quant Cytol Histol 1999; 21:240-4.
64. Tanaka F, Kawano Y, Li M, Takata T, Miyahara R, Yanagihara K, et al. Prognostic significance of apoptotic index in completely resected nonsmall-cell lung cancer. J Clin Oncol 1999; 17:2728-36. (Pubitemid 29415229)
65. Macluskey M, Baillie R, Chandrachud LM, Pendleton N, Schor AM. High levels of apoptosis are associated with improved survival in nonsmall cell lung cancer. Anticancer Res 2000; 20:2123-8. (Pubitemid 30636195)
66. Hwang JH, Lim SC, Kim YC, Park KO, Ahn SJ, Chung WK. Apoptosis and bcl-2 expression as predictors of survival in radiation-treated nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys 2001; 50:13-8.
67. Puglisi F, Minisini AM, Aprile G, Barbone F, Cataldi P, Artico D, et al. Balance between cell division and cell death as predictor of survival in patients with nonsmall-cell lung cancer. Oncology 2002; 63:76-83. (Pubitemid 34977941)
68. Langendijk H, Thunnissen E, Arends JW, de Jong J, ten Velde G, Lamers R, et al. Cell proliferation and apoptosis in stage III inoperable nonsmall cell lung carcinoma treated by radiotherapy. Radiother Oncol 2000; 56:197-207.
69. Kato T, Kameoka S, Kimura T, Tanaka S, Nishikawa T, Kobayashi M. p53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer. Anticancer Res 2002; 22:1105-12. (Pubitemid 34836158)
70. de Jong JS, van Diest PJ, Baak JP. Number of apoptotic cells as a prognostic marker in invasive breast cancer. Br J Cancer 2000; 82:368-73. (Pubitemid 30045383)
71. Reed JC. Bcl-2 family proteins. Oncogene 1998; 17:3225-36. (Pubitemid 29043975)
72. Graflund M, Sorbe B, Karlsson M. Immunohistochemical expression of p53, bcl-2, and p21(WAF1/CIP1) in early cervical carcinoma: Correlation with clinical outcome. Int J Gynecol Cancer 2002; 12:290-8. (Pubitemid 34787557)
73. Tjalma WA, Weyler JJ, Bogers JJ, Pollefliet C, Baay M, Goovaerts GC, et al. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2001; 97:223-30. (Pubitemid 32645659)
74. Dimitrakakis C, Kymionis G, Diakomanolis E, Papaspyrou I, Rodolakis A, Arzimanoglou I, et al. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol Oncol 2000; 77:129-36. (Pubitemid 30217316)
75. Pillai MR, Jayaprakash PG, Nair MK. bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma. J Cancer Res Clin Oncol 1999; 125:55-60. (Pubitemid 29062337)
76. Rajkumar T, Rajan S, Baruah RK, Majhi U, Selvaluxmi G, Vasanthan A. Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. Eur J Gynaecol Oncol 1998; 19:556-60. (Pubitemid 29008297)
77. Harima Y, Harima K, Shikata N, Oka A, Ohnishi T, Tanaka Y. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol 1998; 124:503-10. (Pubitemid 28474161)
78. Crawford RA, Caldwell C, Iles RK, Lowe D, Shepherd JH, Chard T. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br J Cancer 1998; 78:210-4. (Pubitemid 28302258)
79. Uehara T, Kuwashima Y, Izumo T, Kishi K, Shiromizu K, Matsuzawa M. Expression of the proto-oncogene bcl-2 in uterine cervical squamous cell carcinoma: Its relationship to clinical outcome. Eur J Gynaecol Oncol 1995; 16:453-60.
80. Lo Muzio L, Mignogna MD, Pannone G, Rubini C, Grassi R, Nocini PF, et al. Expression of bcl-2 in oral squamous cell carcinoma: An immunohistochemical study of 90 cases with clinicopathological correlations. Oncol Rep 2003; 10:285-91.
81. Kuropkat C, Venkatesan TK, Caldarelli DD, Panje WR, Hutchinson J, Preisler HD, et al. Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx. Auris Nasus Larynx 2002; 29:165-74. (Pubitemid 34230368)
82. Casado S, Forteza J, Dominguez S, Abad MT, Perez I, Intxaurbe I, et al. Predictive value of P53, BCL-2, and BAX in advanced head and neck carcinoma. Am J Clin Oncol 2002; 25:588-90. (Pubitemid 35453666)
83. Wilson GD, Saunders MI, Dische S, Richman PI, Daley FM, Bentzen SM. bcl-2 expression in head and neck cancer: An enigmatic prognostic marker. Int J Radiat Oncol Biol Phys 2001; 49:435-41. (Pubitemid 32120241)
84. Homma A, Furuta Y, Oridate N, Nakano Y, Yagi K, Nagahashi T, et al. Correlation of clinicopathological parameters and biological markers related to apoptosis and proliferative activity with a clinical outcome in squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy. Auris Nasus Larynx 2001; 28 Suppl:S87-94.
85. Dijkema IM, Struikmans H, Dullens HF, Kal HB, van der Tweel I, Battermann JJ. Influence of p53 and bcl-2 on proliferative activity and treatment outcome in head and neck cancer patients. Oral Oncol 2000; 36:54-60.
86. Xie X, Clausen OP, De Angelis P, Boysen M. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999; 86:913-20. (Pubitemid 29439843)
87. Homma A, Furuta Y, Oridate N, Nakano Y, Kohashi G, Yagi K, et al. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 1999; 5:801-6. (Pubitemid 29180831)
88. Gallo O, Chiarelli I, Boddi V, Bocciolini C, Bruschini L, Porfirio B. Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer 1999; 84:573-9.
89. Giatromanolaki A, Koukourakis M, Zaramboukas T, Skordalaki A, Arapantoni P, Georgoulias V, et al. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy. Anticancer Res 1998; 18:4685-92. (Pubitemid 29042044)
90. Gasparini G, Bevilacqua P, Bonoldi E, Testolin A, Galassi A, Verderio P, et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1995; 1:1375-83.
91. Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, Hart AA, et al. Prognostic factors in transitional cell cancer of the bladder: An emerging role for Bcl-2 and p53. Radiother Oncol 2001; 61:169-75.
92. Cooke PW, James ND, Ganesan R, Burton A, Young LS, Wallace DM. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int 2000; 85:829-35. (Pubitemid 30242786)
93. Pollack A, Wu CS, Czerniak B, Zagars GK, Benedict WF, McDonnell TJ. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 1997; 3:1823-9. (Pubitemid 27444723)
94. Rodel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Gunther K, et al. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002; 178:426-35. (Pubitemid 34847422)
95. Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 2001; 8:305-10. (Pubitemid 32422855)
96. Paradiso A, Simone G, Lena MD, Leone B, Vallejo C, Lacava J, et al. Expression of apoptosis- related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer 2001; 84:651-8. (Pubitemid 32238999)
97. Kim NK, Park JK, Lee KY, Yang WI, Yun SH, Sung J, et al. p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol 2001; 8:418-24.
98. Giatromanolaki A, Sivridis E, Stathopoulos GP, Fountzilas G, Kalofonos HP, Tsamandas A, et al. Bax protein expression in colorectal cancer: Association with p53, bcl-2 and patterns of relapse. Anticancer Res 2001; 21:253-9.
99. Ogura E, Senzaki H, Yamamoto D, Yoshida R, Takada H, Hioki K, et al. Prognostic significance of Bcl-2, Bcl-xL/S, Bax and Bak expressions in colorectal carcinomas. Oncol Rep 1999; 6:365-9.
100. Leahy DT, Mulcahy HE, O'Donoghue DP, Parfrey NA. bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology 1999; 35:360-7. (Pubitemid 29502355)
101. Tannapfel A, Nusslein S, Fietkau R, Katalinic A, Kockerling F, Wittekind C. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 1998; 41:585-91. (Pubitemid 28275088)
102. Schneider HJ, Sampson SA, Cunningham D, Norman AR, Andreyev HJ, Tilsed JV, et al. Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Br J Cancer 1997; 75:427-31. (Pubitemid 27051061)
103. Baretton GB, Diebold J, Christoforis G, Vogt M, Muller C, Dopfer K, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 1996; 77:255-64.
104. Sinicrope FA, Hart J, Michelassi F, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1995; 1:1103-10.
105. Bosari S, Moneghini L, Graziani D, Lee AK, Murray JJ, Coggi G, et al. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 1995; 26:534-40.
106. McDonald FE, Ironside JW, Gregor A, Wyatt B, Stewart M, Rye R, et al. The prognostic influence of bcl-2 in malignant glioma. Br J Cancer 2002; 86:1899-904.
107. Deininger MH, Weller M, Streffer J, Meyermann R. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma. Cancer 1999; 86:1832-9. (Pubitemid 29513054)
108. Kraus JA, Wenghoefer M, Glesmann N, Mohr S, Beck M, Schmidt MC, et al. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J Neurooncol 2001; 52:263-72. (Pubitemid 33638526)
109. Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, et al. BCL-2 family protein expression in initial and recurrent glioblastomas: Modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 1999; 67:763-8.
110. Heesters MA, Koudstaal J, Go KG, Molenaar WM. Proliferation and apoptosis in long-term surviving low grade gliomas in relation to radiotherapy. J Neurooncol 2002; 58:157-65. (Pubitemid 34790203)
111. Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J, Meyermann R. BCL-2 family protein expression in human malignant glioma: A clinical-pathological correlative study. J Neurol Sci 1998; 155:68-75. (Pubitemid 28141061)
112. Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 2003; 97:1630-8. (Pubitemid 36350706)
113. Szostak MJ, Kaur P, Amin P, Jacobs SC, Kyprianou N. Apoptosis and bcl-2 expression in prostate cancer: Significance in clinical outcome after brachytherapy. J Urol 2001; 165:2126-30.
114. Scherr DS, Vaughan Jr ED, Wei J, Chung M, Felsen D, Allbright R, et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 1999; 162:12-6; discussion 16-7.
115. Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 1998; 52:1085-90. (Pubitemid 28533381)
116. Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD, White RW. p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 1998; 51:346-51. (Pubitemid 28093197)
117. Bylund A, Stattin P, Widmark A, Bergh A. Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy. Radiother Oncol 1998; 49:143-148. (Pubitemid 29017908)
118. Rakozy C, Grignon DJ, Sarkar FH, Sakr WA, Littrup P, Forman J. Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy. Mod Pathol 1998; 11:892-9. (Pubitemid 28440887)
119. Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Vonlanthen S, Hotz MA, et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected nonsmall-cell lung cancer. Br J Cancer 1999; 79:952-8. (Pubitemid 29082132)
120. Cox G, Walker RA, Muller S, Abrams KR, Steward WP, O'Byrne KJ. Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in nonsmall cell lung cancer? Pathol Oncol Res, 2000; 6:87-92.
121. Laudanski J, Chyczewski L, Niklinska WE, Kretowska M, Furman M, Sawicki B, et al. Expression of bcl-2 protein in nonsmall cell lung cancer: Correlation with clinicopathology and patient survival. Neoplasma 1999; 46:25-30. (Pubitemid 29166935)
122. Ohsaki Y, Toyoshima E, Fujiuchi S, Matsui H, Hirata S, Miyokawa N, et al. bcl-2 and p53 protein expression in nonsmall cell lung cancers: Correlation with survival time. Clin Cancer Res 1996; 2:915-20. (Pubitemid 26169993)
123. Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, et al. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in nonsmall cell lung cancers. Cancer Sci 2003; 94:394-9.
124. Zhang GJ, Kimijima I, Tsuchiya A, Abe R. The role of bcl-2 expression in breast carcinomas (Review). Oncol Rep 1998; 5:1211-6. (Pubitemid 28372589)
125. Chen HH, Su WC, Guo HR, Chang TW, Lee WY. p53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan. Jpn J Clin Oncol 2002; 32:332-9. (Pubitemid 43102785)
126. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996; 14:1604-10. (Pubitemid 26134219)
127. Kymionis GD, Dimitrakakis CE, Konstadoulakis MM, Arzimanoglou I, Leandros E, Chalkiadakis G, et al. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? J Surg Res, 2001; 99:161-8.
128. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000; 6:2751-8. (Pubitemid 30482114)
129. Sjostrom J, Blomqvist C, von Boguslawski K, Bengtsson NO, Mjaaland I, Malmstrom P, et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 2002; 8:811-6. (Pubitemid 34742112)
130. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148:1567-76. (Pubitemid 26135897)
131. Nakopoulou L, Michalopoulou A, Giannopoulou I, Tzonou A, Keramopoulos A, Lazaris AC, et al. bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining. Histopathology 1999; 34:310-319. (Pubitemid 29229985)
132. Scopa CD, Vagianos C, Kardamakis D, Kourelis TG, Kalofonos HP, Tsamandas AC. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol 2001; 9:329-34. (Pubitemid 33098142)
133. Cascinu S, Graziano F, Catalano V, Staccioli MP, Rossi MC, Baldelli AM, et al. An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. Br J Cancer 2002; 86:744-9. (Pubitemid 34250817)
134. Harima Y, Nagata K, Harima K, Oka A, Ostapenko VV, Shikata N, et al. Bax and Bcl-2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIB cervical carcinoma. Cancer 2000; 88:132-8. (Pubitemid 30027688)
135. Ikeguchi M, Maeta M, Kaibara N. Bax expression as a prognostic marker of postoperative chemoradiotherapy for patients with esophageal cancer. Int J Mol Med 2001; 7:413-7.
136. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with nonsmall cell lung cancer: A meta-analysis. Clin Cancer Res 2000; 6:4055-63.
137. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br J Cancer 1999; 80:1968-73. (Pubitemid 29391282)
138. Thames HD, Petersen C, Petersen S, Nieder C, Baumann M. Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data. Strahlenther Onkol 2002; 178:411-21. (Pubitemid 34847420)
139. Altieri DC, Marchisio PC, Marchisio C. Survivin apoptosis: An interloper between cell death and cell proliferation in cancer. Lab Invest 1999; 79: 1327-33.
140. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: Characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999; 59:3143-51. (Pubitemid 29316014)
141. Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 2003; 29:379-82. (Pubitemid 36675696)
142. Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003; 23:3327-31. (Pubitemid 36975431)
143. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, et al. Prognostic importance of survivin in breast cancer. Br J Cancer 2003; 88:1077-83. (Pubitemid 36560779)
144. Kappler M, Kotzsch M, Bartel F, Fussel S, Lautenschlager C, Schmidt U, et al. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 2003; 9:1098-104. (Pubitemid 36323717)
145. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, et al. Expression of survivin in astrocytic tumors: Correlation with malignant grade and prognosis. Cancer 2003; 97:1077-83. (Pubitemid 36173161)
146. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, Heine B, Stein H, Hopfner M, et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003; 88:115-9. (Pubitemid 36241227)
147. Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, Nofroni I, et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003; 14:85-90.
148. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R. Survivin expression in ovarian carcinoma: Correlation with apoptotic markers and prognosis. Mod Pathol 2003; 16:574-83. (Pubitemid 36718439)
149. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 2002; 184:105-16. (Pubitemid 34718112)
150. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 2002; 21:315-20.
151. Nakanishi K, Tominaga S, Hiroi S, Kawai T, Aida S, Kasamatsu H, et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch 2002; 441:559-63. (Pubitemid 35435825)
152. Ikeguchi M, Kaibara N. survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer 2002; 87:883-7. (Pubitemid 35252964)
153. Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol 2002; 11:33-40. (Pubitemid 34171210)
154. Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res 2002; 22:2377-83. (Pubitemid 34857069)
155. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002; 20:1063-8. (Pubitemid 34141851)
156. Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 2001; 163:109-16. (Pubitemid 32121836)
157. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, et al. Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer 2001; 95:92-5. (Pubitemid 32187079)
158. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6:127-34. (Pubitemid 30064984)
159. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000; 46:645-50. (Pubitemid 30305781)
160. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, et al. A novel anti-apoptosis gene: Reexpression of survivin messenger RNA as a prognosis marker in nonsmall-cell lung cancers. J Clin Oncol 1999; 17:2100-4. (Pubitemid 29318841)
161. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif 1991; 24:203-14.
162. Dive C, Hickman JA. Drug-target interactions: Only the first step in the commitment to a programmed cell death? Br J Cancer, 1991; 64:192-6.
163. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352:345-7. (Pubitemid 21912356)
164. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992; 89:4495-9.
165. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362:847-9. (Pubitemid 23132161)
166. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362:849-52. (Pubitemid 23132162)
167. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-67. (Pubitemid 23289454)
168. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-10. (Pubitemid 24359290)
169. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace Jr AJ, Kohn KW, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 275:343-9. (Pubitemid 27051604)
170. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59:1391-9. (Pubitemid 29160097)
171. Endlich B, Radford IR, Forrester HB, Dewey WC. Computerized video time-lapse microscopy studies of ionizing radiation-induced rapid-interphase and mitosis-related apoptosis in lymphoid cells. Radiat Res 2000; 153:36-48. (Pubitemid 30117082)
172. Zamble DB, Jacks T, Lippard SJ. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci USA 1998; 95:6163-8. (Pubitemid 28248982)
173. Aldridge DR, Arends MJ, Radford IR. Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival dose-response. British Journal of Cancer 1995; 71:571-7.
174. Han JW, Dionne CA, Kedersha NL, Goldmacher VS. p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc. Cancer Research 1997; 57:176-82. (Pubitemid 27020349)
175. Lock RB, Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Research 1996; 56:4006-12. (Pubitemid 26284752)
176. Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M, et al. Caspase-independent cell death in AML: Caspase-inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 2003; in press.
177. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Research 1991; 51:6304-11.
178. Brown JM. NCI's anticancer drug screening program may not be selecting for clinically active compounds. Oncol Res 1997; 9:213-5.
179. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408-16. (Pubitemid 28193601)
180. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997; 3:1034-6. (Pubitemid 27391962)
181. Wouters BG, Giaccia AJ, Denko NC, Brown JM. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis- independent mechanism. Cancer Res 1997; 57:4703-6. (Pubitemid 27468970)
182. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104:263-9.
183. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000; 6:1029-35.
184. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978; 298:1321-7. (Pubitemid 8357629)
185. Schlag P, Flentje D. Chemosensitivity testing of human neoplasms using the soft agar colony assay. Cancer Treat Rev 1984; 11 Suppl A:131-7. (Pubitemid 16022599)
186. Radford IR. Radiation response of mouse lymphoid and myeloid cell lines. Part I. Sensitivity to killing by ionizing radiation, rate of loss of viability, and cell type of origin. Int J Radiat Biol 1994; 65:203-15. (Pubitemid 24097193)
187. Bearss DJ, Subler MA, Hundley JE, Troyer DA, Salinas RA, Windle JJ. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene 2000; 19:1114-22. (Pubitemid 30153798)
188. Kemp CJ, Sun S, Gurley KE. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res 2001; 61:327-32. (Pubitemid 32095734)
189. Wouters BG, Denko NC, Giaccia AJ, Brown JM. A p53 and apoptotic independent role for p21waf1 in tumour response to radiation therapy. Oncogene 1999; 18:6540-5.
190. Forrester HB, Albright N, Ling CC, Dewey WC. Computerized video time-lapse analysis of apoptosis of REC:Myc cells X- irradiated in different phases of the cell cycle. Radiat Res 2000; 154:625-39.
191. Dewey WC, Miller HH, Leeper DB. Chromosomal aberrations and mortality of X-irradiated mammalian cells: Emphasis on repair. Proc. Natl. Acad. Sci. USA 1971; 68:667-71.
192. Carrano AV. Chromosome aberrations and radiation-induced cell death. II. Predicted and observed cell survival. Mutat. Res. 1973; 17:355-66.
193. Bedford JS, Mitchell JB, Griggs HG, Bender MA. Radiation-induced cellular reproductive death and chromosome aberrations. Radiat Res 1978; 76:573-86. (Pubitemid 9067024)
194. Deschner EE, Gray LH. Influence of oxygen on the sensitivity of Tradescantia pollen tube chromosomes to X-rays. Radiation Res 1959; 11:115-47.
195. Schneider DO, Whitmore GF. Comparative effects of neutrons and x-rays on mammalian cells. Radiation Res 1963; 18:286-306.
196. Lloyd DC, Edwards AA Chromosome aberrations in human lymphocytes: Effect of radiation quality, dose, and dose-rate. In: Ishihara T, Sasaki MS, eds. Radiation-Induced Chromosome Damage in Man New York: Alan R. Liss, 1983:23-49.
197. Bedford JS, Cornforth MN. Relationship between the recovery from sublethal X-ray damage and the rejoining of chromosome breaks in normal human fibroblasts. Radiat Res 1987; 111:406-23. (Pubitemid 17144555)
198. Cornforth MN, Bedford JS. On the nature of a defect in cells from individuals with ataxia- telangiectasia. Science 1985; 227:1589-91. (Pubitemid 15119467)
199. Stackhouse MA, Bedford JS. An ionizing radiation-sensitive mutant of CHO cells: Irs-20. III. Chromosome aberrations, DNA breaks and mitotic delay. Int J Radiat Biol 1994; 65:571-82. (Pubitemid 24167409)
200. Revell SH. The breakage-and-reunion theory and the exchange theory for chromosomal aberrations induced by ionizing radiations: A short history. Advances in Radiation Biology 1974; 4:367-416.
201. Damia G, Imperatori L, Stefanini M, D'Incalci M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 1996; 66:779-83. (Pubitemid 26197946)
202. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9:568-74. (Pubitemid 36597103)
203. Park SY, Lam W, Cheng YC. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 2002; 62:459-65. (Pubitemid 34106419)
204. Boulton S, Kyle S, Durkacz BW. Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin. Eur J Cancer 2000; 36:535-41. (Pubitemid 30136235)
205. Murray D. DNA repair in resistance to bifunctional alkylating and platinating agents. Cancer Treat Res, 2002; 112:129-60.
206. Simon JA, Szankasi P, Nguyen DK, Ludlow C, Dunstan HM, Roberts CJ, et al. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res 2000; 60:328-33. (Pubitemid 30070759)
207. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 87:293-8. (Pubitemid 8177356)
208. Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH, et al. Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 2003; 9:767-73. (Pubitemid 36182613)
209. Masters JR, Koberle B. Curing metastatic cancer: Lessons from testicular germ-cell tumours. Nat Rev Cancer 2003; 3:517-25. (Pubitemid 37328839)
210. Bedford P, Fichtinger-Schepman AM, Shellard SA, Walker MC, Masters JR, Hill BT. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 1988; 48:3019-24.
211. Koberle B, Payne J, Grimaldi KA, Hartley JA, Masters JR. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol 1996; 52:1729-34. (Pubitemid 26407988)
212. Agarwal R, Kaye SB. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3:502-16. (Pubitemid 37328838)
213. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3:46-54. (Pubitemid 37328886)